Please tell us about your professional/clinical experience.

What can you tell us about the prostate-specific membrane antigen and the imaging analysis technology (aBSI and PSMA AI) pipeline of Progenics; how does it compare to detection methods of prostate cancer presently in use?

In what % of the patient population do you find low grade prostate cancer after biopsy, and what is the follow-up patient surveillance and treatment plan?

What percent of the patient population is in Active Surveillance; and how regularly does a patient usually get tested ?

Previously released data for PyL showed a 96-99% specificity, with the lower bound of the 95th percent confidence interval (94-96%) exceeding 80%. The sensitivity of 31-42%, did not meet the second co-primary endpoint, as the lower bound of the 95th percentile confidence interval (19-30%) did not exceed the required 40%. The positive predictive value and negative predictive value of pelvic lymph node detection were 78-91% and 81-84%, respectively. In the metastatic or recurrent prostate cancer setting (Cohort B), PyL exhibited sensitivity of 93-99% and PPV of 81-88% in detecting metastatic lesions. How do you interpret this data?

 Axumin(fluciclovine F 18) can detect recurrent disease with PSA levels less than 10. PyL’s rate is 93-99% in detecting metastatic prostate cancer lesions and 96-99 in confirming the absence of pelvic lymph node disease. How do they compare, and what would make you choose PyL over Axumin?

How useful is Choline C 11 Injection+PET Scan for finding the prostate cancer distribution in the body? How often does Prostate Cancer spread throughout the body? Can PyL compete with it?

How would you rank Imaging Agents and Analysis technology by Diagnostic Accuracy and ability to detect metastatic prostate cancer within the within the prostate gland and pelvic lymph nodes, or within sites of metastasis and local recurrence?

How would you rank Detection Methods by false-positive rates?